Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
CLNNW 
Clene Inc (CLNNW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/23/2025: CLNNW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -70% | Avg. Invested days 20 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/23/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 646.98M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 0.48 | 52 Weeks Range 0.02 - 0.08 | Updated Date 05/16/2025 |
52 Weeks Range 0.02 - 0.08 | Updated Date 05/16/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -5032.1% |
Management Effectiveness
Return on Assets (TTM) -49.62% | Return on Equity (TTM) -1738.36% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 6140786 |
Shares Outstanding - | Shares Floating 6140786 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
Clene Inc
Company Overview
History and Background
Clene Inc. is a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for neurodegenerative diseases. Founded in 2012, the company is dedicated to engineering and manufacturing clean-surface nanocrystals that address mitochondrial dysfunction and energy deficit in neurodegenerative diseases.
Core Business Areas
- Neurodegenerative Disease Therapeutics: Clene focuses on developing therapeutic candidates for conditions like amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), and Parkinson's disease by leveraging its proprietary catalytic nanotherapeutic (CNT) platform.
Leadership and Structure
Clene Inc. is led by Rob Etherington (President & CEO) and a management team with experience in biotechnology and pharmaceuticals. The company has a board of directors that oversees its strategic direction and operations.
Top Products and Market Share
Key Offerings
- CNM-Au8: CNM-Au8 is Clene's lead therapeutic candidate, an investigational oral gold nanocrystal suspension. It targets neuronal energetic failure in neurodegenerative diseases. Clinical trials are ongoing for ALS, MS, and Parkinson's disease. Market share data is unavailable due to the investigational nature of the product. Competitors include companies developing treatments for ALS (e.g., Biogen), MS (e.g., Novartis, Biogen), and Parkinson's disease (e.g., AbbVie).
Market Dynamics
Industry Overview
The biopharmaceutical industry focused on neurodegenerative diseases is large and growing, driven by an aging population and increasing prevalence of these conditions. The market is highly competitive with many companies pursuing different therapeutic approaches.
Positioning
Clene is positioning itself as a leader in the development of catalytic nanotherapeutics for neurodegenerative diseases. Its CNT platform represents a novel approach to addressing mitochondrial dysfunction, differentiating it from other companies in the field.
Total Addressable Market (TAM)
The TAM for neurodegenerative disease treatments is substantial, estimated to be in the tens of billions of dollars annually. Clene is positioned to capture a portion of this market if its therapeutic candidates are successful in clinical trials and receive regulatory approval.
Upturn SWOT Analysis
Strengths
- Novel CNT platform
- Promising preclinical and clinical data
- Experienced management team
- Strong intellectual property portfolio
Weaknesses
- Early stage clinical development
- High cash burn rate
- Dependence on successful clinical trial outcomes
- Limited commercialization experience
Opportunities
- Positive clinical trial results
- Partnerships with larger pharmaceutical companies
- Expansion into new indications
- Regulatory approval and commercialization
Threats
- Clinical trial failures
- Competition from existing therapies
- Regulatory hurdles
- Funding constraints
Competitors and Market Share
Key Competitors
- BIIB
- NVS
- ABBV
- TEVA
Competitive Landscape
Clene's competitive advantage lies in its CNT platform. However, it faces competition from larger pharmaceutical companies with established products and resources.
Growth Trajectory and Initiatives
Historical Growth: Clene's growth has been primarily driven by its research and development activities and advancement of its clinical programs.
Future Projections: Future growth is dependent on successful clinical trial outcomes and regulatory approval of its therapeutic candidates. Analyst estimates vary and should be consulted for specific growth projections.
Recent Initiatives: Recent initiatives include ongoing clinical trials for CNM-Au8 in ALS, MS, and Parkinson's disease.
Summary
Clene Inc. is a high-risk, high-reward biopharmaceutical company with a novel therapeutic approach for neurodegenerative diseases. Its success hinges on the outcome of its clinical trials. While its innovative platform offers promise, it faces significant competition and financial challenges.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Clene Inc. Investor Relations
- SEC Filings
- Industry Reports
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Market share data and financial metrics are estimates based on available information and are subject to change. Consult with a qualified financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Clene Inc
Exchange NASDAQ | Headquaters Salt Lake City, UT, United States | ||
IPO Launch date 2020-12-31 | CEO, President & Director Mr. Robert Etherington MBA | ||
Sector Consumer Defensive | Industry Packaged Foods | Full time employees 75 | Website https://clene.com |
Full time employees 75 | Website https://clene.com | ||
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution. In addition, it markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.